Ziltivekimab Evidence: Trial Results and Peer-Reviewed Publications

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

1. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives.
   Kreiner FF, Kraaijenhof JM, von Herrath M, et al. · Expert Rev Clin Immunol · 2022
   PubMed: PMID 35212585 · NCT03926117 (RESCUE) · Inflammation
2. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial.
   Wada Y, Jensen C, Meyer ASP, et al. · J Cardiol · 2023
   PubMed: PMID 37211246 · NCT04626505 (RESCUE-2) · Inflammation
3. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
   Ridker PM, Devalaraja M, Baeres FMM, et al. · Lancet · 2022
   PubMed: PMID 34015342 · NCT03926117 (RESCUE) · Inflammation
4. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
   Pergola PE, Davidson M, Jensen C, et al. · J Am Soc Nephrol · 2024
   PubMed: PMID 38088558 · NCT03926117 (RESCUE) · Inflammation
5. Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort.
   Mohammadnia N, van Broekhoven A, Bax WA, et al. · Atherosclerosis · 2025
   PubMed: PMID 40318255 · NCT05021835 (ZEUS) · Inflammation
6. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.
   Hu S, Lee K, He JC, et al. · Clin J Am Soc Nephrol · 2026
   PubMed: PMID 41805697 · NCT03926117 (RESCUE) · Inflammation
7. Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities.
   Byambaa E, Roshanravan B, Berglund L, et al. · Clin J Am Soc Nephrol · 2025
   PubMed: PMID 41329869 · NCT05021835 (ZEUS) · Inflammation
8. GWAS breakthroughs: mapping the journey from one locus to 393 significant coronary artery disease associations.
   Aherrahrou R, Reinberger T, Hashmi S, et al. · Cardiovasc Res · 2024
   PubMed: PMID 39073758 · NCT03926117 (RESCUE) · Inflammation

Publications by year

2022–2026: 8 publications.

Publications by indication

Publications by journal

• Clin J Am Soc Nephrol2 papers
• Expert Rev Clin Immunol1 paper
• J Cardiol1 paper
• Lancet1 paper
• J Am Soc Nephrol1 paper
• Atherosclerosis1 paper
• Cardiovasc Res1 paper

All Ziltivekimab publications (8)

Sources and methodology

• Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
• Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
• Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
• Data freshness: Thu, 14 May 2026 22:09:30 GMT.